Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia.
Deguchi
N
N
Kawamura
T
T
Shimizu
A
A
Kitamura
R
R
Yanagi
M
M
Shibagaki
N
N
Matsue
H
H
Shimada
S
S
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007645:Keratoderma, Palmoplantar / Q000139:chemically induced; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009260:Nail Diseases / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate